Skip to main content
OpenTrials
Completed

NCT Number: NCT06242600

Evaluation of Safety and Performance of the CytaCoat Lubricious Infection Prevention (LIP) Foley Catheter

The goal of this pilot safety and tolerability study is to determine whether the novel CytaCoat LIP (Lubricious Infection Prevention) Foley catheter is safe to use in patients during short term use.

The primary objective of this study is to determine the safety and tolerability for the medical device CytaCoat LIP Foley catheter in patients undergoing Transurethral Resection of the Bladder (TUR-B) surgery. Safety will be assessed by evaluation of adverse events.

The secondary objective is to assess the overall performance by evaluating if there were any Foley catheter handling problems experienced by the healthcare personnel with the use of the CytaCoat LIP Foley catheter.

Exploratory objectives are to assess bacterial culture of urine samples taken before and after catheterization and to assess pain, irritation and discomfort measured by asking patients about their experience using the catheter using a questionnaire.

Participants will be catheterized with either a CytaCoat Foley catheter or an uncoated silicone catheter, for a maximum of 24 hrs. After removal of the catheter, participants will be asked to assess if they experienced any pain, irritation and discomfort measured with the Numerical Rating Scale (NRS) (0-10). A similar assessment will be performed 7-10 days after removal of the catheter. In addition, the healthcare personnel will be asked to assess the functionality of the coated catheter with the NRS scale (0-10), using a questionnaire. Urine samples will be taken before and after catheterization and evaluated through quantification.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–84 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Sahlgrenska University Hospital

Gothenburg, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Will be undergoing a TUR-B procedure.
  • Able to give informed consent by signing and dating the written informed consent document acknowledging their desire to participate in the study.
  • Adults, age 18 to 84 years.
  • Require insertion of a size 12, 14, 16, 18 or 20 French Foley catheter after TUR-B surgery.
  • Be able to understand and comply with the information given in the Patient Consent Form.

Exclusion criteria

  • Vulnerable subjects such as children, pregnant or breastfeeding women, or potentially immune-compromised subjects.
  • Unable to provide informed consent.
  • Has a known bacteriuria or a current urinary tract infection.
  • Has a known bloodstream infection or an infection that requires prolonged antibiotic therapy.
  • Has an ongoing antibiotic therapy.
  • Cannot accommodate a size 12, 14, 16, 18 or 20 Fr Foley catheter or requires a Thiemann tip Foley catheter.
  • Previous enrolment in the present study.
  • Simultaneous participation in another clinical study that may impact the primary endpoint.
  • Severe non-compliance to protocol as judged by the PI.

Treatment and study plan

Drainage of the bladder by indwelling Foley catheter

Device

Drainage of the bladder by transurethral catheterization with an indwelling Foley catheter of patients undergoing a TUR-B procedure and in need of a Foley catheter for up to 24 hrs.

Other names: CytaCoat LIP Foley catheter

Primary outcomes

  1. Assessment of incidence of adverse events and serious adverse events (safety and tolerability) of the CytaCoat LIP Foley catheter

    Time frame: 1 - 10 days

    Adverse events (AEs) and serious adverse events (SAEs) will be assessed, which are further divided into adverse device effects (ADEs) and serious ADEs (SADEs).

Secondary outcomes

  1. Assessment of the overall performance of the CytaCoat LIP Foley catheter

    Time frame: 1 - 10 days

    The functionality of the coated catheter will be assessed by a responsible nurse/physician with the NRS scale (0-10) using questionnaires.

Other outcomes

  1. Exploratory assessment of bacterial culture of urine samples

    Time frame: 1 - 48 hours

    Assessment by quantitative bacterial culture of urine samples obtained from patients when first included in the study and subsequently after clamping the catheter for 30 minutes prior to extirpation of the catheter.

  2. Exploratory assessment of patient user experience of the CytaCoat LIP Foley catheter

    Time frame: 1 - 10 days

    Assessment immediately after removal of the catheter of pain, irritation and discomfort measured with the NRS scale (0-10) using a questionnaire asking patients about their experience using the catheter.

    Assessment 7-10 days after removal of the catheter of pain, irritation and discomfort measured with the NRS scale (0-10) using a questionnaire asking patients about their experience using the catheter.

Sponsors and collaborators

Lead sponsor

CytaCoat AB

Industry

Registry information

Official study title

A Prospective Single-center Randomized Pilot Study to Evaluate the Safety and Performance of the Novel CytaCoat LIP Foley Catheter When Compared to an Uncoated Foley Catheter

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Feb 5, 2024
Registry last updated
Nov 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.